These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38881915)

  • 1. The analysis of the efficacy and safety of stereotactic body radiotherapy with sequential immune checkpoint inhibitors in the management of oligoprogressive advanced non-small cell lung cancer.
    Ying X; You G; Shao R
    Transl Cancer Res; 2024 May; 13(5):2408-2418. PubMed ID: 38881915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.
    Wang Z; Wei L; Li J; Zhou H; Li S; Chen D; Yu Y; Zhao L; Zhu X; Song Y
    Transl Lung Cancer Res; 2021 Dec; 10(12):4368-4379. PubMed ID: 35070747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
    Tsai CJ; Yang JT; Shaverdian N; Patel J; Shepherd AF; Eng J; Guttmann D; Yeh R; Gelblum DY; Namakydoust A; Preeshagul I; Modi S; Seidman A; Traina T; Drullinsky P; Flynn J; Zhang Z; Rimner A; Gillespie EF; Gomez DR; Lee NY; Berger M; Robson ME; Reis-Filho JS; Riaz N; Rudin CM; Powell SN;
    Lancet; 2024 Jan; 403(10422):171-182. PubMed ID: 38104577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
    Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Xu Y; Li H; Fan Y
    Front Oncol; 2021; 11():642883. PubMed ID: 33747966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy.
    Tsur E; Blumenfeld P; Rottenberg Y; Nechushtan H; Arnon J; Wald O; Izhar U; Pfeffer R; Krakow A; Wygoda M; Popovtzer A; Michaeli TF
    Transl Lung Cancer Res; 2024 Mar; 13(3):465-474. PubMed ID: 38601442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiotherapy prolongs the progression-free survival and delays the change of systemic therapy regimen in patients with lung oligoprogressive metastatic colorectal cancer.
    Li S; Dong D; Geng J; Zhu X; Shi C; Zhang Y; Wang H; Zhou S; Wu H; Cai Y; Li Y; Wang W
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e64-e72. PubMed ID: 33629479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
    Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
    Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.
    Joosten PJM; de Langen AJ; van der Noort V; Monkhorst K; Klomp HM; Veenhof AAFA; Dickhoff C; Smit EF; Hartemink KJ
    Lung Cancer; 2021 Nov; 161():141-151. PubMed ID: 34600405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study.
    Brown LJ; Ahn J; Gao B; Gee H; Nagrial A; Pires da Silva I; Hau E
    JTO Clin Res Rep; 2024 Oct; 5(10):100695. PubMed ID: 39429236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy.
    Sindhu KK; Nehlsen AD; Lehrer EJ; Rowley JP; Stock RG; Galsky MD; Buckstein M
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Bahig H; Tonneau M; Blais N; Wong P; Filion E; Campeau MP; Vu T; Al-Saleh A; Tehfé M; Florescu M; Roberge D; Masucci L; Richard C; Menard C; Routy B
    Clin Transl Radiat Oncol; 2022 Mar; 33():115-119. PubMed ID: 35243022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer.
    Ebadi M; Ladbury C; Liu J; Rock A; Onyshchenko M; Villaflor V; Villalona-Calero M; Salgia R; Massarelli E; Lee P; Williams T; Amini A
    Clin Lung Cancer; 2023 Nov; 24(7):651-659. PubMed ID: 37714807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of failure and the subsequent treatment after progression on first-line immunotherapy monotherapy in advanced non-small cell lung cancer: a retrospective study.
    Deng JY; Yang MY; Yang XR; Chen ZH; Xu CR; Zhou Q
    BMC Cancer; 2024 Sep; 24(1):1190. PubMed ID: 39333978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
    Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
    J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
    Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
    Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
    Liu Z; Xu T; Chang P; Fu W; Wei J; Xia C; Wang Q; Li M; Pu X; Huang F; Ge C; Gao Y; Gong S; Liu C; Dong L
    Front Pharmacol; 2023; 14():1064227. PubMed ID: 36762107
    [No Abstract]   [Full Text] [Related]  

  • 19. Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy.
    Huet C; Basse C; Knetki-Wroblewska M; Chilczuk P; Bonte PE; Cyrille S; Gobbini E; Du Rusquec P; Olszyna-Serementa M; Daniel C; Lucibello F; Lahmi L; Krzakowski M; Girard N
    Clin Lung Cancer; 2024 Dec; 25(8):e402-e410.e3. PubMed ID: 39214846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy.
    Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; Tanadini-Lang S; Mayinger M; Guckenberger M; Andratschke N
    Clin Transl Radiat Oncol; 2024 Mar; 45():100748. PubMed ID: 38433950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.